With no potential neurodegenerative disease link target, 18alpha-glycyrrhetinic acid can be considered the most potent and specific drug candidate against CST, while in the case of β-carotene, transthyretin and RBP4 may act as cross-targets in the brain (Pinheiro et al., 2022; Ishii et al., 2019). Here, GAL3ST1 is linked to neurodegenerative disease.